Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From The World Insiders

Supreme Court to take up LGBT job discrimination cases

Apr 22, 2019

WASHINGTON — The Supreme Court will decide whether the main federal civil rights law that prohibits employment discrimination applies to LGBT people. The justices say Monday they will hear cases involving people who claim they were fired because of their sexual orientation. Another case involves a funeral home employee who was fired after disclosing that she was transitioning from male to female and dressed as a woman. The cases will be argued in the fall, with decisions likely by June 2020 in the middle of the presidential election campaign. The issue is whether Title VII of the federal Civil Rights...

New York outbreaks drive US measles count up to 626

Apr 22, 2019

NEW YORK — Outbreaks in New York state continue to drive up the number of U.S. measles cases, which are approaching levels not seen in 25 years. Health officials say 71 more cases were reported last week, with 68 of them from New York. That brings this year's total to 626. That is already the most since 2014, when 667 were reported for the whole year. The most before that was 963 cases in 1994. Twenty-two states have reported cases, but the vast majority have been in New York — mainly in New York City and in nearby Rockland County....

Trump, business organization sue Democratic House chairman

Apr 22, 2019

WASHINGTON — President Donald Trump and his business organization have sued the Democratic chairman of the House oversight committee to block a subpoena that seeks years of the president's financial records. Rep. Elijah Cummings issued the subpoena earlier this month to Mazars USA, an accountant for the president and Trump Organization. The complaint filed in federal court in Washington says the subpoena seeks to investigate events that occurred before Trump was president and "has no legitimate legislative purpose." It says "Democrats are using their new control of congressional committees to investigate every aspect of President Trump's personal finances, businesses, and...

'Today' co-anchor Jenna Bush Hager expecting 3rd child

Apr 22, 2019

NEW YORK — "Today" show co-anchor Jenna Bush Hager is pregnant with her third child. The 37-year-old journalist shared the news with colleagues during Monday morning's show. The announcement comes less than a week after her co-anchor, Hoda Kotb, announced she had adopted her second child. She joined the fourth hour of the "Today" show as co-host earlier this month when Kathie Lee Gifford stepped down from her role . Hager, and her husband, Henry, are the parents of daughters 6-year-old Mila and 3-year-old Poppy. The children's grandparents are former President George W. Bush and his wife, Laura.

Markets Right Now: Stocks open lower, crude oil prices rise

Apr 22, 2019

NEW YORK — The latest on developments in financial markets (all times local): 9:35 a.m. Stocks are opening mostly lower on Wall Street following a long holiday weekend, while energy stocks rose along with crude oil prices. Benchmark U.S. crude oil rose 2.4% early Monday after the U.S. said it wouldn't renew waivers to five countries exempting them from sanctions if they continued to import oil from Iran. Marathon Oil jumped 2.7%. Other energy companies also rose. Elsewhere, technology stocks and companies that rely on consumer spending posted some of the biggest losses. Western Digital fell 2.3% and Mattel dropped...

About Us

The World Insiders brings you exclusive coverage from across the globe in a timely, easy to consume format sourced directly from our regional media partners.

Contact us: sales[at]theworldinsiders.com

Subscribe Now!